前立腺癌に対するEstramustine Phosphate(Estracyt)療法の臨床的,内分泌学的検討

Abstract

Evaluation of therapeutic effects and endocrinological studies of Estramustine Phosphate (Estracyt/EMP) were made in 14 patients with prostatic carcinoma. Seven out of 14 patients without previous antiandrogenic medication showed objective response to EMP treatment. In the other patients with relapse, one showed subjective response but 6 showed no response to EMP treatment. Plasma LH, FSH, testosterone and 5a-dihydrotestosterone were measured by a specific radioimmunoassay in 10 patients with prostatic carcinoma before and during EMP treatment. The clinical statuses of the 10 patients were as follows: Four had received no treatment before EMP administration; namely fresh cases, the other 4 had been treated inadequately; namely false reactivated cases and the remainder were true reactivated cases. Plasma testosterone, 5a-dihydrotestosterone and gonadotropins concentrations decreased significantly in fresh cases and false reactivated cases. The cases of true reactivation showed no change in plasma testosterone and 5a-dihydrotestosterone levels after administration of EMP. From the results mentioned above, it was noted that no significant difference of hormonal effect was found between oral administration of 560 mg/day EMP, 200 mg/day diethylstilbesterol-diphosphate and 30 mg/day hexestrol.